Related Experiment Video

Updated: Apr 4, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K

Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention

Lucia H Lee1, Xin-Xing Gu2, Moon H Nahm3

  • 1Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA. Lucia.Lee@fda.hhs.gov.

Vaccines
|September 8, 2015
PubMed

Insights

The seven-valent pneumococcal conjugate vaccine (PCV7) reduced disease globally, but non-PCV7 serotypes, including the newly identified 6C, still cause significant Streptococcus pneumoniae burden. Future vaccines are needed to address remaining disease risks.

Area of Science:

  • Microbiology
  • Vaccinology
  • Epidemiology

Background:

  • The seven-valent pneumococcal conjugate vaccine (PCV7) has significantly decreased the global burden of Streptococcus pneumoniae disease.
  • Disease caused by serotypes not included in PCV7 remains a global health concern.
  • Serotype 6C, a newly recognized pathogen, was previously misidentified as serotype 6A.

Purpose of the Study:

  • To review the epidemiology of pneumococcal disease before and after PCV7 introduction.
  • To analyze post-marketing surveillance data for higher valency vaccines (PCV10, PCV13).
  • To discuss future directions in pneumococcal vaccine development.

Main Methods:

  • Literature review of pneumococcal serotype epidemiology.
  • Analysis of surveillance data for PCV7, PCV10, and PCV13 impact.
  • Synthesis of current knowledge on pneumococcal serotypes and vaccine efficacy.

Main Results:

  • PCV7 introduction led to a decline in vaccine-type invasive pneumococcal disease.
  • Non-vaccine serotypes, including 6C, have emerged or persisted.
  • Higher valency vaccines show broader serotype coverage and impact.

Conclusions:

  • Despite PCV7 success, residual pneumococcal disease burden necessitates ongoing surveillance and vaccine development.
  • Addressing emerging and non-vaccine serotypes is crucial for comprehensive disease prevention.
  • Future pneumococcal vaccines should aim for broader serotype coverage to minimize disease impact.

Keywords:
Streptococcus pneumoniaeepidemiologypneumococcal proteinserotypevaccine

More Related Videos

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.4K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.9K

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.0K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Preventive Healthcare Services01:30

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
2.3K
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
47
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K